Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2026-03-20 @ 2:37 AM
Study NCT ID:
NCT01613118
Status:
COMPLETED
Last Update Posted:
2025-05-15
First Post:
2012-06-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Sponsor:
Travere Therapeutics, Inc.